Ozmosi | BHV-2100 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

BHV-2100

Alternative Names: BHV-2100, BHV2100, BHV 2100
Clinical Status: Active
Latest Update: 2025-07-08
Latest Update Note: Clinical Trial Update

Product Description

BHV-2100 is a first-in-class molecule directed against TRPM3, a novel druggable target in the transient receptor potential (TRP) cation channel family. (Sourced from: https://www.biohaven.com/pipeline/discovery-research/trpm3/)

Mechanisms of Action: TRPM3 Antagonist

Novel Mechanism: Yes

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BHV-2100

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Migraine Disorders

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06603623

 BHV2100-201

P2

Completed

Migraine Disorders

2025-03-24

2025-07-09

Primary Completion Date|Primary Endpoints|Study Completion Date

Recent News Events

Date

Type

Title

01/13/2025

News Article

 Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy

09/30/2024

News Article

 Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

05/29/2024

News Article

 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

01/08/2024

News Article

 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions